Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Phase 3 Completed 514 enrolled Eli Lilly and Company Boehringer Ingelheim · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.

Timeline

Start: 2005-03
Primary completion: 2008-01
Completion: 2008-01

Outcome

Met primary endpoint

paper Time to a depressive recurrence was significantly longer in duloxetine-treated patients compared with placebo-treated patients (p < .001). PMID 19552867 ↗

Publications

Perahia DG, Maina G, Thase ME, Spann ME, Wang F, Walker DJ, Detke MJ. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 May;70(5):706-16. doi: 10.4088/jcp.08m04756.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	60 mg	Oral
Subject	Duloxetine	Small molecule	120 mg	Oral